Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

why are millions of eligible Americans still avoiding colon cancer screening? Simply put, many people find the traditional options — colonoscopy and stool-based tests — unpleasant or inconvenient.

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY ...

One’s biological age, which measures the body’s physiological state, may help predict who is at risk for developing colon ...

Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal cancer ... a patient’s stool sample to identify genetic mutations that may lead to a cancer diagnosis.

The ColoAlert test, which utilizes polymerase chain reaction (PCR) technology to detect colorectal cancer DNA in stool samples, aims to provide an early detection method for the disease.

However, combined with other signs like blood in stool, weight loss, or abdominal pain, it warrants further investigation. Colorectal cancer is on the rise in recent decades especially in young or ...